Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Mease

Showing results (131-140 of 175) with videos related to

Pageof 18
Sort By:
Seminars in Arthritis and Rheumatism|September 14, 2020
Clinical trial discrimination of physical function instruments for psoriatic arthritis: A systematic reviewYing-Ying Leung, Richard Holland, Ashish J Mathew, et al.
The Open Rheumatology Journal|January 13, 2017
Fibromyalgia Outcomes Over Time: Results from a Prospective Observational Study in the United StatesCaroline P Schaefer, Edgar H Adams, Margarita Udall, et al.
Annals of the Rheumatic Diseases|July 15, 2020
Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52Josef S Smolen, Philip Mease, Hasan Tahir, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 28, 2026
Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical TrialJoseph F Merola, Philip Mease, Alan Kivitz, et al.
Seminars in Arthritis and Rheumatism|August 16, 2021
OMERACT Filter 2.1 instrument selection for physical function domain in psoriatic arthritis: Provisional endorsement for HAQ-DI and SF-36 PFYing-Ying Leung, Ana-Maria Orbai, Pil Hojgaard, et al.
Research Square|October 27, 2023
An NKG2A biased immune response confers protection for infection, autoimmune disease, and cancerJames Heath, Daniel Chen, Jingyi Xie, et al.
The Journal of Rheumatology. Supplement|June 3, 2019
Proceedings of the 2018 GRAPPA Collaborative Research Network MeetingDeepak R Jadon, Vinod Chandran, Alexis Ogdie, et al.
Lancet (London, England)|October 27, 2018
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trialDésirée van der Heijde, James Cheng-Chung Wei, Maxime Dougados, et al.
Lancet (London, England)|July 3, 2018
Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind studyRobert Landewé, Joachim Sieper, Philip Mease, et al.
Arthritis and Rheumatism|March 2, 2012
Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trialArthur Kavanaugh, Désirée van der Heijde, Iain B McInnes, et al.
Pageof 18

Showing results (131-140 of 175) with videos related to

Sort By:
Pageof 18
Seminars in Arthritis and Rheumatism|September 14, 2020
Clinical trial discrimination of physical function instruments for psoriatic arthritis: A systematic reviewYing-Ying Leung, Richard Holland, Ashish J Mathew, et al.
The Open Rheumatology Journal|January 13, 2017
Fibromyalgia Outcomes Over Time: Results from a Prospective Observational Study in the United StatesCaroline P Schaefer, Edgar H Adams, Margarita Udall, et al.
Annals of the Rheumatic Diseases|July 15, 2020
Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52Josef S Smolen, Philip Mease, Hasan Tahir, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 28, 2026
Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical TrialJoseph F Merola, Philip Mease, Alan Kivitz, et al.
Seminars in Arthritis and Rheumatism|August 16, 2021
OMERACT Filter 2.1 instrument selection for physical function domain in psoriatic arthritis: Provisional endorsement for HAQ-DI and SF-36 PFYing-Ying Leung, Ana-Maria Orbai, Pil Hojgaard, et al.
Research Square|October 27, 2023
An NKG2A biased immune response confers protection for infection, autoimmune disease, and cancerJames Heath, Daniel Chen, Jingyi Xie, et al.
The Journal of Rheumatology. Supplement|June 3, 2019
Proceedings of the 2018 GRAPPA Collaborative Research Network MeetingDeepak R Jadon, Vinod Chandran, Alexis Ogdie, et al.
Lancet (London, England)|October 27, 2018
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trialDésirée van der Heijde, James Cheng-Chung Wei, Maxime Dougados, et al.
Lancet (London, England)|July 3, 2018
Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind studyRobert Landewé, Joachim Sieper, Philip Mease, et al.
Arthritis and Rheumatism|March 2, 2012
Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trialArthur Kavanaugh, Désirée van der Heijde, Iain B McInnes, et al.
Pageof 18